Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Chemical Works of Gedeon RichterRGEDF +3.37%97 EBITDA Margin % is 20.96% as of Jun. 2026, which is 24% below its 10-year median of 27.58. GuruFocus rates RGEDF with a GF Score™ of 97/100 and a GF Value™ of $36.36 (Modestly Overvalued). The stock has 7 warning signs investors should review. Among 958 Drug Manufacturers companies, Chemical Works of Gedeon Richter ranks better than 92.8% on this metric.
Chemical Works of Gedeon Richter (OTCPK:RGEDF) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Chemical Works of Gedeon Richter EBITDA Margin % Related Terms
Chemical Works of Gedeon Richter EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chemical Works of Gedeon Richter EBITDA Margin % Chart
RGEDF vs ZTS, UTHR, VTRS: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Chemical Works of Gedeon Richter's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chemical Works of Gedeon Richter EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Chemical Works of Gedeon Richter's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Chemical Works of Gedeon Richter's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chemical Works of Gedeon Richter (RGEDF) has a EBITDA Margin % of 20.96% as of Jun. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Chemical Works of Gedeon Richter and its competitors. This is 24% below median its historical median of 27.58. Over the past decade, Chemical Works of Gedeon Richter's EBITDA Margin % has ranged from 11.17 to 40.33. According to the industry distribution chart, Chemical Works of Gedeon Richter ranks #69 out of 958 companies in the Drug Manufacturers industry, placing it in the top 7.2%.
Is Chemical Works of Gedeon Richter's EBITDA Margin % too high?
Chemical Works of Gedeon Richter's current EBITDA Margin % of 20.96% is 24% below median its 10-year median of 27.58. Over the past 10 years, this metric has ranged from a low of 11.17 to a high of 40.33. The Drug Manufacturers industry median EBITDA Margin % is 12.11. Chemical Works of Gedeon Richter's value of 20.96% is 73.2% above this industry median. Based on the distribution chart, Chemical Works of Gedeon Richter ranks #69 out of 958 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Chemical Works of Gedeon Richter has a GF Score™ of 97/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Chemical Works of Gedeon Richter's EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Chemical Works of Gedeon Richter ranks #69 out of 958 companies for EBITDA Margin %. This places Chemical Works of Gedeon Richter in the top 7% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 12.11. Chemical Works of Gedeon Richter's value of 20.96% is 73.2% above this benchmark. Historically, Chemical Works of Gedeon Richter's own EBITDA Margin % has ranged from 11.17 to 40.33 over the past decade. While the company's 10-year median is 27.58 vs. the industry median of 12.11, Chemical Works of Gedeon Richter has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.11, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Chemical Works of Gedeon Richter's current EBITDA Margin % of 20.96% is 73.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Chemical Works of Gedeon Richter and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.11 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chemical Works of Gedeon Richter's current EBITDA Margin % is 20.96%, which is 24% below median its own 10-year median of 27.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chemical Works of Gedeon Richter stock overvalued right now?
Based on GuruFocus' analysis, Chemical Works of Gedeon Richter (RGEDF) is currently considered Modestly Overvalued. The stock's GF Value™ is $36.36, compared to a current price of $41.48 — trading 14.1% above its estimated fair value. The current EBITDA Margin % is 20.96%, which is 24% below median its 10-year median of 27.58 and 73.2% above the Drug Manufacturers industry median of 12.11. Chemical Works of Gedeon Richter's overall GF Score™ is 97/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Chemical Works of Gedeon Richter (RGEDF), the current EBITDA Margin % is 20.96% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chemical Works of Gedeon Richter (RGEDF) Overvalued in 2026?
Based on GuruFocus' analysis, Chemical Works of Gedeon Richter stock appears to be overvalued.
The current stock price of $41.48 is trading 14.1% above its estimated GF Value™ of $36.36.
GuruFocus considers Chemical Works of Gedeon Richter to be Modestly Overvalued.
Key valuation signals for RGEDF:
EBITDA Margin %: 20.96% (24% below median its 10-year median of 27.58)
GF Value™: $36.36 vs. price of $41.48 (14.1% above fair value)
Industry Position: 73.2% above the Drug Manufacturers median (#69 of 958)
No single metric tells the full story. See the RGEDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chemical Works of Gedeon Richter PLC is a pharmaceutical company. The company focuses on the development and manufacture of gynaecological, cardiovascular, and central nervous system products. It manufactures medicines including original, generic and licensed products for treatment in the therapeutic area. The group is active in two business segments namely, the Pharma segment comprising Women's Healthcare, Neuropsychiatry, Biotechnology, General Medicine, and Other pharma; and the Others segment includes the remaining wholesale and retail business of the Group and all other activities. The company operates internationally.
97GF Score
Get the complete analysis for RGEDF
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RGEDF has been successfully added to your 
